Summit Therapeutics plc - רווח למניה אחת ב-12 החודשים האחרונים SMMT

High clinical trial risks and patent protection form the business foundation of Summit Therapeutics (SMMT). The 12-month YoY earnings per share growth rate on this GURU.Markets platform chart reflects a trend where 13.80 becomes the new value for this metric. Production relies on external contractors and foreign laboratories. Summit Therapeutics (SMMT) is currently building an oncology ecosystem while awaiting FDA approval to capture the lung cancer therapy market.

Summit Therapeutics develops unique oncology drugs, aiming for long-term monopoly dominance in the cancer therapy market. The annual dynamics of the EPS TTM metric reflect the rate of change in net income per share, comparing the current twelve months with the same period last year. This method smooths out quarterly reporting gaps, revealing the real trend of business efficiency. Analysis of this chart allows for the timely detection of profit stagnation and prevents overpaying for the asset.